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Abstract
In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn’s dis-
ease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were
investigated as production method for stable powders. Dextran and inulin were used in
combination with sucrose as stabilizing excipients. The drying processes did not affect
Infliximab in these formulations, i.e. both the physical integrity and biological activity (TNF
binding) were retained. Accelerated stability studies (1 month at 60˚C) showed that the
TNF binding ability of Infliximab was conserved in the freeze-dried formulations, whereas
the liquid counterpart lost all TNF binding. After thermal treatment, the dried formulations
showed some chemical modification of the IgG in the dextran-sucrose formulation, proba-
bly due to Maillard reaction products. This study indicates that, with the appropriate formu-
lation, both spray-drying and freeze-drying may be useful for (bulk) powder production of
Infliximab.
Introduction
Therapeutic antibodies are among the most important biopharmaceuticals. Therapeutic pro-
teins in liquid may require a cold chain during storage and transport as they may be prone to
physical and chemical degradation. In order to improve their stability, therapeutic proteins are
often dried by methods such as freeze-dryingor spray-drying [1, 2]. By removal of water, the
protein stability increases as degradation pathways and protein mobility are reduced in the
dried state.
In the pharmaceutical industry, freeze-drying is the most commonly usedmethod, to dry
therapeutic antibodies [3]. Generally, freeze-drying is performed using vials. After freezing, ice
is removed by sublimation (primary drying stage) and water is removed by desorption (second-
ary drying stage) [4–8]. Lyoguard trays have been developed for drying bulk volumes of liquid
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into bulk powder that can easily be collected and processed further by cryo-milling [9]. A maxi-
mum of 1800 ml of liquid can be dried in one Lyoguard tray. The tray top is made of semiper-
meable membrane that permits water vapor to pass through. The membrane is not permeable
to microorganisms and therefore sterility of the product being dried is maintained. [4, 10].
Although extensive research has been carried out on lyophilization of monoclonal antibody
(mAbs) in vials [2, 11–13], there is little published data on freeze-dryingof pharmaceuticals in
Lyoguard trays [14].
Spray-drying on the other hand starts with the nebulization of a liquid. The droplets are
dried via evaporation in a continuous airflow. The evaporation cools the droplets, preventing
high-temperature-exposure of the product [8, 15–17]. The shear stress generated during nebu-
lization may affect the product quality but can beminimized by addition of excipients [18].
In order to successfully dry antibodies and especially to retain their biological activity during
drying and subsequent storage, stabilizing excipients are required. Saccharides or polyols are
the most commonly used stabilizers for drying of proteins [11, 19, 20]. A number of studies
have reported that sugars are thought to provide the stabilization effect by forming a sugar
glass matrix that reduces diffusion and molecularmobility of proteins thereby protecting the
biological product [21, 22]. Moreover, during the drying process the hydrogen bonds between
the water molecules and protein are replaced by bonds with the hydroxyl groups of the sugar,
thereby maintaining the structural integrity of the protein [23, 24]. Non-reducing sugars, like
sucrose and trehalose are widely used excipients. Moreover, polysaccharides like inulin and
dextran have been described as excipients that can increase the temperature (glass transition
temperature, Tg) above which the glass to rubber transition of the dried powder may take place
[25].
In this study, Infliximab is formulated using sucrose and the polysaccharides inulin or dex-
tran in order to produce dry powder bulk material by spray-drying or freeze-drying.Infliximab
is a mAb against TNF-α and used in the treatment of inflammatory bowel diseases (IBD).
Infliximab neutralizes the effects of Tumor Necrosis Factor-α by binding to the soluble and
transmembrane forms and inhibits binding to its receptors and thus suppressing the inflamma-
tory cascade [26]. In the commercial Infliximab products (e.g. Remicade or Inflectra), the mAb
is formulated using sucrose (50 mg/mL), phosphate buffer and Tween 80 (0.05 mg/mL) and
freeze-dried [19].
The objective of this study was to compare two dryingmethods, freeze-drying(vial vs Lyo-
guard trays) and spray-drying to obtain stable dried Infliximab formulations. Freeze-drying in
Lyoguard trays and spray drying are of interest because of the potential to scale up the drying
process for bulk powder production. This would facilitate the development of an oral [27] or
other dosage form as alternative for the current intravenous administration route [28]. Since
Infliximab acts in the gut, systemic uptake is not necessary. Depending on the route of delivery,
additional research would be required for secondary processing. This study focusses on excipi-
ents and excipient combinations for production of thermostable Infliximab powder
formulations.
Materials and Methods
Excipients
The following materials were used: sucrose (Sigma-Aldrich), polysorbate 80 (Tween 80, Sigma-
Aldrich), inulin (4kD; Sensus, Roosendaal), dextran (5kD; Pharmacosmos Denmark), sodium
dihydrogen phosphate (Sigma-Aldrich), disodiumhydrogen phosphate (Sigma-Aldrich) and 5
mg/mL of Infliximab antibody bulk (5 mg/ml in 5% sucrose and 0.005% (polysorbate 80, pH
7.2) (obtained from AIMM therapeutics).
Spray-Drying and Freeze-Drying of Infliximab
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Infliximab production and purification
Recombinant infliximabwas produced in CHO K1SV cells (Lonza). Infliximab was purified
from CHO supernatants using Mab Sure-resin (GE Healthcare) and gel filtration (Super-
dex200, GE Healthcare). Purified antibodies were formulated in disodiumhydrogen phosphate
(1.2 mg/mL) adjusted to pH 7.2 with sodium dihydrogen phosphate (0.25 mg/mL), 5% sucrose
and 0.005% polysorbate80.
Infliximab formulations
The formulation buffer consists of disodiumhydrogen phosphate (1.2 mg/mL) adjusted to pH
7.2 with sodium dihydrogen phosphate (0.25 mg/mL).
Three formulations were prepared for drying (Table 1).
1. Sucrose based: final concentration of 5% (50 mg/mL) sucrose, 0.005% Tween 80 (polysor-
bate 80) and 5 mg/mL of Infliximab antibody.
2. Sucrose-Inulin based: final concentration of 5% (50 mg/mL) sucrose, 6% (60 mg/mL) inu-
lin, 0.005% Tween 80 (polysorbate 80) and 5 mg/mL of Infliximab antibody.
3. Sucrose-Dextranbased: final concentration of 5% (50 mg/mL) sucrose, 6% (60 mg/mL)
dextran, 0.005% Tween 80 (polysorbate 80) and 5 mg/mL of Infliximab antibody.
These formulations were, lyophilized in glass vials (F), lyophilized in Lyoguard trays (L) or
spray dried (S) resulting in dried formulations. The sucrose based formulation was not spray
dried. The sucrose based formulation acts as a control for the licensed product. Furthermore,
the study focused on sugar excipients (inulin and dextran) which have a high glass transition
temperature and were anticipated to render a thermostable powder.
Freeze-drying (FD)
Drying in glass vials. Vials filledwith 1 mL (11 mL vial, Nuova Ompi, Italy) of the three
formulations F1, F2 and F3 were loaded into a pilot freeze-dryer (Zirbus, The Netherlands)
and subsequently frozen to −40°C by reducing the shelf temperature at a rate of 1°C/min. The
vials were kept at a temperature of −40°C for 2 h. For the primary drying phase, the shelf tem-
perature was increased at a rate of 0.2°C/h to −35°C (while decreasing the chamber pressure to
0.05 mbar) followed by drying for 96 h. The secondary drying phase was performed by further
increasing the shelf temperature at a rate of 0.02°C/min to 25°C at a chamber pressure of 0.01
mbar, followed by 24 h drying at 25°C. At the end of the cycle, the vials were closed under vac-
uum, sealedwith alu-caps and kept at 4°C until analysis.
Drying in Lyoguard trays. The Lyoguard trays (LGT2000, Gore & associates, Tilburg,
The Netherlands) [4] were filledwith 30 mL, 15 mL and 15 mL of the three formulations L1,
Table 1. Formulations classified based on excipients and drying methods.
Drying Method Formulation type
sucrose sucrose-inulin sucrose-dextran
Freeze-dried
-Vials F1 F2 F3
-Lyoguard tray L1 L2 L3
Spray-dried S1 S2
doi:10.1371/journal.pone.0163109.t001
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L2 and L3. Filled Lyoguard trays were loaded into the freeze dryer and dried according to the
same protocol as used for vials (as described above).
Spray drying (SD)
A lab scale B-290 spray dryer was employed in conjunction with a high performance cyclone
and a B-295 dehumidifier (Büchi LabortechnikAG, Flawil, Switzerland) using a closed loop
configuration. Infliximab bulk powders were produced from 30 mL solutions of formulation
S1 and S2 respectively. Production of the powders was performed using the following process
settings: inlet temperature of 120°C, liquid feed flow rate of 1.0 mL/min, atomizing airflow of
667 L/h, and an aspirator flow rate was of 22 m3/hr (the maximum instrument capacity).
Powder collection and further handling
In order to minimize exposure to environmental moisture all powder handling after drying
was performed in a glove box (Terra Universals, series 100 plastic glove box, Fluerton CA,
USA). The relative humidity (RH) was maintained below 3.0% with nitrogen purge in the envi-
ronment, and was monitored using an RH sensor. Spray dried powders were filled in vials and
sealed in glove box. The vials were stored at 2–8°C until further analysis. For accelerated stabil-
ity, study samples were stored at 60°C for 1 month. The choice of this temperature was based
on the melt curve determined by differential scanning fluorimetry for Infliximab liquid samples
(data not shown). The beginning of the melt of–CH2 domain occurs around 60°C. The liquid
infliximab stored at this temperature served as the negative control. Moreover, it is known that
infliximab in dried product is not affected at lower temperatures of 40°C [27].
Residual moisture content analysis (RMC)
The residual moisture content (RMC) was determined using a Water Detection System 400
(Sartorius, Göttingen, Germany). The principle of the analysis is based on as a combination of
a thermal gradient and water detection by gas coulometry using a sensor described elsewhere
[29]. The sample (approximately 20 mg) was introduced in small pans into the oven chamber.
The temperature program included an initial rise of temperature to 100°C and maintained for
3 minutes. It was further raised to 130°C and maintained for 2 minutes. It was raised further to
180°C in 3 minutes. The software from the equipment calculated the final RMC values. All
RMC analysis were performed in triplicate (1 vial for each test, 3 vials in total).
Sample reconstitution and protein concentration determination
The dried Infliximab samples were reconstituted in ultrapure water by gentle swirling, followed
by filtration with a 0.22 μm syringe filter (Whatman). Some sucrose-inulin formulated Inflixi-
mab samples showed some insoluble material after reconstitution, those samples were centri-
fuged (1 min, 16k rpm) and supernatant was used for analysis. The protein concentration in
the reconstituted samples was measured spectrophotometrically, using a Nanodrop 1000 spec-
trophotometer (Thermo Scientific). The reconstituted samples were stored at 4°C.
Size exclusion chromatography
Size exclusion chromatography (SEC) was performed to measure the percentage of soluble pro-
tein aggregates and degradation products. For non-stressed reconstituted Infliximab, 500 μL of
solution containing 1.0 mg IgG was injected on a prep-grade HiPrep Superdex200 16/600 col-
umn (GE Healthcare), equilibrated with Infliximab formulation buffer. PBS was used as the
mobile phase. For temperature stressed Infliximab, 10 μL of 1.0 mg/mL (diluted in PBS)
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antibody was injected on an analytical Sephax Zenix-C SEC300 gel filtration column (Sepax,
Delaware, USA), equilibrated with 150 mMNaPO4, pH 7. The choice of second column was
based on the rationale that it has a higher separation efficiency (5–1250 kDa) for separating
aggregates compared to HiPrep Superdex (10–600 kDa). During elution, the absorbance was
measured by a UV-detector set at a wavelength of 215 nm and 280 nm. The percentage of
aggregation was calculated using UNICORN 5.0 software (GE Healthcare).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE)
To determine possible antibody fragmentation, non-reducing and reducing SDS-PAGE was
performed using a 4–20%mini Protean TGX gradient gel (BIORAD). Reconstituted Infliximab
samples, containing 2.0 μg mAb, were diluted into 20 μL of XT SDS-PAGE sample buffer
(Biorad, The Netherlands). When indicated samples were reduced, DTT (Biorad, The Nether-
lands) was added to a final concentration of 5 mM. Samples were incubated at 95°C for 5 min-
utes before loading on the gel. Dual color protein standard (Biorad, The Netherlands) was used
as a molecular weight ladder. Protein bands were visualized by staining the gels with BioSafe
Coomassie stain (Biorad, The Netherlands) and destained in ultrapure water. Stained gels were
imaged on a GelDoc imager (Biorad, The Netherlands).
IgG ELISA
The IgG content of the reconstituted samples was determinedwith an ELISA. The 96-well
ELISA plate (Costar, #3590) was coated overnight at 4°C with polyclonal goat-anti-human-
IgG-Fc (5 ug/mL in PBS; Jackson) 100 μL per well. The plate was washed three times with
wash-buffer (PBS containing 0.05% Tween 80) followed by blocking for 2 hours with blocking
buffer (1%m/v fish skin gelatin, Roche). The control and reconstituted Infliximab samples
were filtered with a 0.22 μm syringe filter (Whatman) and a dilution series in blocking buffer
with a starting concentration of 500 ng/mL, diluted to 1 ng/mL (according to Nanodrop mea-
surement), was added to the plate. For stressed samples, a starting concentration of 1000 ng/
mL was used. After 5x washing, 100 μL of detection antibody goat-anti-human-IgG HRP con-
jugate (Jackson) was added and incubated for 1 hour at room temperature. After 2 washing 5x,
boundHRP-conjugate was detectedwith tetramethyl benzidine (TMB) as the peroxidase sub-
strate. The enzymatic reaction was allowed to proceed at room temperature for 3 min and
stopped by adding 50 μL of 1 M sulfuric acid. The absorbance was measured at a wavelength of
450 nm using an Envision plate reader (Perkin Elmer). Based on different dilutions, the data
was calculated back to the theoretical concentration of 5 mg/mL.
TNF-Capture ELISA
The TNF-binding capacity of Infliximab was quantified by a capture ELISA. The method in
brief as follows: a 96-well ELISA plate was coated overnight at 4°C with mouse-anti-human
TNFα capture antibody (1:400; Pelikan TNF kit, Abcam) 100 μL per well. The plate was
washed three times with wash buffer (PBS containing 0.05% Tween80) followed by blocking
for 2 hours with the blocking buffer (1%m/v fish skin gelatin, Roche). Later, 100 μL of solution
containing 10 ng/mL in blocking buffer Human-rTNFα (Life Technologies) was added and
incubated for 1h at room temperature. After washing, 100 μL of diluted Infliximab control in
blocking buffer (500 ng/mL) and reconstituted samples were added to the corresponding wells.
This was followed by addition of 100 μL of detection antibody–goat-anti-IgGHRP (Jackson)
was added and incubated for 1h at room temperature. The bound antibody was detectedwith
tetramethyl benzidine (TMB) as peroxidase substrate. The enzymatic reaction was allowed to
Spray-Drying and Freeze-Drying of Infliximab
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proceed at room temperature for 3 min and stopped by adding 50 μL of 1 M sulfuric acid. The
absorbance was measured at a wavelength of 450 nm using (an Envision plate reader (Perkin
Elmer). The data is represented as actual concentration vs absorbance.
Results and Discussion
In order to produce an Infliximab containing powder, different dryingmethods and excipient
combinations were evaluated. In addition, an accelerated stability study was performed (at 60°C)
to examine whether the thermal stability would be affected by the composition of the formulation.
Antibody powder properties
After drying and storage at 2–8°C. Spray-drying (SD) and freeze-drying(FD) in Lyo-
guard trays were investigated as dryingmethods for production of dried Infliximab
Table 2. Residual moisture content of dried Infliximab formulations.
Drying Method RMC of Infliximab Formulation (%)
Freeze-dried Sucrose sucrose-inulin sucrose-dextran
-Vials 3.9 ± 0.3 1.1 ± 0.1 1.2 ± 0.1
-Lyoguard tray 2.6 ± 0.2 2.4 ± 0.3 2.5 ± 0.3
Spray-dried - 1.2 ± 0.1 1.5 ± 0.2
doi:10.1371/journal.pone.0163109.t002
Fig 1. A. T = 0 Non-reducing SDS-PAGE analysis of reconstituted Infliximab samples. M: Dual color protein standard, 1: commercial Infliximab,
2: Infliximab (AIMM), Freeze-dried (vials) 3: sucrose-based (F1), 4: sucrose-inulin (F2), 5: sucrose-dextran (F3), Freeze-dried (Lyoguard trays) 6:
sucrose-inulin (L2), 7: sucrose-dextran (L3), Spray–dried 8: sucrose-inulin (S1), 9: sucrose-dextran (S2). B.T = 0 Reducing SDS-PAGE of
reconstituted Infliximab samples. M: Dual color protein standard, 1: commercial Infliximab, 2: Infliximab (AIMM), Freeze-dried (vials) 3: sucrose-
based (F1), 4: sucrose-inulin (F2), 5: sucrose-dextran (F3), Freeze-dried (Lyoguard trays) 6: sucrose-inulin (L2), 7: sucrose-dextran (L3), Spray–
dried 8: sucrose-inulin (S1), 9: sucrose-dextran (S2).
doi:10.1371/journal.pone.0163109.g001
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formulations. In order to compare with the standard dryingmethod used for current marketed
Infliximab products, each Infliximab formulation was also freeze-dried in vials. Independent of
the dryingmethod used, the RMC of all but one formulations were below 3% (Table 2), the rec-
ommended RMC limit for dried biologicals [30]. The exception was the RMC of freeze-dried
sucrose formulation (F1). A lower residual moisture content is preferred since an increased
water content in the dried formulation may affect the protein stability, for example through
aggregate formation caused by the plasticizing effect of water (lower glass transition tempera-
ture and subsequent increase in molecularmobility). The selected SD and FD processes were
suitable for producing dried Infliximab product within the prescribed RMC limits for the inu-
lin and dextran containing formulations. The product obtained from FDmay require a cryo-
milling step [9] to obtain powder form. In addition, it was found that drying in Lyoguard trays
resulted in a higher RMC than drying in vials, except for the sucrose-based formulation. The
increase in RMC could probably be due to the reducedmoisture removal caused by the mem-
brane barrier.
Analysis of non-dried Infliximab and reconstituted Infliximab by size exclusion chromatog-
raphy (SEC) showed the presence of intact IgG without degradation products for all samples
(data not shown). This interpretation was confirmed by SDS-PAGE analysis (see Fig 1A and
1B). Fig 1A shows the expected IgG band at around 150 kDa under non-reduced conditions
and antibody fragments at 50 kDa (IgG1 heavy chain) and 25 kDa (kappa light chain) under
reduced conditions (see Fig 1B, reduced samples). This demonstrates that the dryingmethods
did not affect the Infliximab backbone. Thus, all samples consist of intact monomeric IgG, irre-
spective of the applied drying process or formulation. In addition, the IgG content of the recon-
stituted dried Infliximab formulations measured by the Nanodrop spectrophotometer was
found to be in line with the theoretical concentration (data not shown). Apparently, the insolu-
ble material observed in Inulin containing formulations did not contain any protein.
Fig 2. A. T = 1 month (60˚C) gel filtration runs of reconstituted Infliximab samples. Commercial Infliximab
(Remicade) stored at 4˚C shown in black. Samples dried in sucrose based buffer shown in blue. Samples dried
with sucrose-inulin excipients shown in red. Samples dried with sucrose-dextran based excipient shown in orange.
B. T = 1 month (60˚C) Non-reducing SDS-PAGE analysis of reconstituted Infliximab samples stored at 60˚C. M:
Dual color protein standard, 1: commercial Infliximab (stored at 4˚C), Freeze-dried (vials) 2: sucrose-based (F1), 3:
sucrose-inulin (F2), 4: sucrose-dextran (F3), Freeze-dried (Lyoguard trays) 5: sucrose-based (L1), 6: sucrose-
inulin (L2), 7: sucrose-dextran (L3), Spray–dried 8: sucrose-inulin (S1), 9: sucrose-dextran (S2). C. T = 1 month
(60˚C) Reducing SDS-PAGE analysis of reconstituted Infliximab samples stored at 60˚C. M: Dual color protein
standard, 1: commercial Infliximab (stored at 4˚C, Freeze-dried (vials) 2: sucrose-based (F1), 3: sucrose-inulin
(F2), 4: sucrose-dextran (F3), Freeze-dried (Lyoguard trays) 5: sucrose-based (L1), 6: sucrose-inulin (L2), 7:
sucrose-dextran (L3), Spray–dried 8: sucrose-inulin (S1), 9: sucrose-dextran (S2).
doi:10.1371/journal.pone.0163109.g002
Table 3. The percentage of antibody aggregates determined by SEC present in samples after storage
at 60˚C for 1 month. In case of non-stressed sample, material was stored at 2–8˚C.
Formulation Type Method Aggregation (% of total)
Liquid (non-stressed) 0.0
Sucrose F1 0.2
L1 0.2
Sucrose-inulin F2 0.7
L2 1.2
S1 1.1
Sucrose-dextran F3 0.6
L3 1.1
S2 2.6
doi:10.1371/journal.pone.0163109.t003
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After accelerated stability storage—1month at 60°C. All Infliximab samples were incu-
bated at a temperature of 60°C for 1 month. At these extreme conditions, liquid Infliximab for-
mulated with sucrose and Tween 80 readily aggregated and precipitated. Storage of liquid
Infliximab at 60°C for 3 days results in visible aggregation. The filtrate was analyzed for IgG
content and less than 1% was recovered.
The SEC chromatograms showed the presence of small amounts of IgG degradation/ reaction
products in all powders (Fig 2A). The sucrose formulated Infliximab formulations showed least
aggregation (see Table 3). In spray-dried sucrose-dextran powder, aggregation was most evident.
There was also evidence for adduct formation as concluded from the broadened IgG peak
from SEC analysis in the formulation with dextran. The dextran-sucrose formulations
showed an increase in molecular weight of the IgG as well as smearing of the antibody band,
indicating heterogeneous chemical addition (Fig 2B, lanes 4, 7, 9). The reducing SDS-PAGE
analysis indicated modifications to the heavy chain in the dextran-sucrose based formulations,
as evidencedby smearing of the protein band at 50 kDa (Fig 2C, lane 4, 7 and 9). These findings
may be explained by the occurrence of IgG-dextran adducts formation by the well-known
Maillard reaction [31]. Inulin-sucrose based formulations show extra bands at around ±100
kDa (Fig 2C, lane 3, 6 and 8) suggesting a possible dimerization via two heavy chain crosslinks.
Inulin contains reducing groups [32] and can react with amino groups of proteins resulting in
possible crosslinking. This observationwas limited to storage at elevated temperatures. One
would not suspect such extent of modifications during storage at lower temperatures (<25°C).
Preservation of Biological activity
After drying and storage at 2–8°C. The biological activity of Infliximab was assessed by
determining its TNF binding ability. There was a minimal difference between the untreated
control and Infliximab powders immediately after drying (Fig 3). This is in accordance with
SEC and SDS-page analysis. Obviously, the dryingmethod and formulation composition
hardly affected the antibody’s ability to bind to TNFα. This was also in line with the IgG recov-
ery of freshly dried samples when compared to the theoretical value (Table 4).
Fig 3. A. T = 0 TNF binding assay of reconstituted freeze-dried in vials Infliximab formulations. Control:
Infliximab (AIMM, stored at 4˚C), Freeze-dried (vials): sucrose-based (F1), sucrose-inulin (F2) and sucrose-
dextran (F3). B. T = 0 TNF binding assay of reconstituted freeze-dried in Lyoguard trays Infliximab
formulations. Control: Infliximab (AIMM, stored at 4˚C), Freeze-dried (Lyoguard trays): sucrose-inulin (L2)
and sucrose-dextran (L3). C.T = 0 TNF binding assay of reconstituted spray-dried Infliximab formulations.
Control: Infliximab (AIMM, stored at 4˚C), Spray-dried: sucrose-inulin (S1) and sucrose-dextran (S2).
doi:10.1371/journal.pone.0163109.g003
Table 4. The IgG concentrations observed by IgG ELISA for Infliximab samples.
Formulation
Type
Method Theoretical IgG concentration (mg/
mL)
IgG concentration(mg/mL)Day
0
IgG concentration (mg/mL)Day 30
at60˚C
Sucrose F1 5.0 4.3 ± 0.04 4.3 ± 0.07
L1 5.0 5.1 ± 0.05 4.6 ± 0.10
Sucrose-Inulin F2 5.0 4.5 ± 0.06 4.2 ± 0.06
L2 5.0 5.6 ± 0.02 4.0 ± 0.25
S1 5.0 4.6 ± 0.04 2.4 ± 0.27
Sucrose-Dextran F3 5.0 4.4 ± 0.05 3.6 ± 0.09
L3 5.0 5.1 ± 0.05 4.8 ± 0.04
S2 5.0 4.6 ± 0.06 2.3±0.05
Infliximab (AIMM) Liquid
control
10.0 9.17 ± 0.03 0.06 ± 0.007 (day 7)
doi:10.1371/journal.pone.0163109.t004
Spray-Drying and Freeze-Drying of Infliximab
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After accelerated stability storage—1month at 60°C. Spray-dried Infliximab formulations
showed a decreasedTNF binding ability after storage at elevated temperatures (Fig 4C). This
observationwas in line with the reduced IgG recovery of both spray-dried Infliximab samples
after storage at 60°C (see Table 4). Surprisingly, no such reduction in IgG recovery or TNF bind-
ing ability (Fig 4A and 4B) was noted in the freeze-dried formulations stored at 60°C, which is
remarkable since both Lyoguard samples had a higher RMC than the spray-dried samples.
Concluding Remarks
Freeze-dryingand spray-drying were shown to be successful methods for producing Infliximab
powders, using three different sugar combinations for drying. The monoclonal antibody
retained its physical stability and TNF binding ability during the drying process. Compared to
the liquid formulation, drying clearly improved the stability of the Infliximab. Spray-dried for-
mulations showed a reduced thermostability (at 60°C) compared to the freeze-driedproducts
as concluded from aggregate formation. Both aggregates and Maillard reaction products are
unwanted because these may increase the potential risk of clinical immunogenicity [33, 34]. A
real time stability study might be useful to examine whether formation of these reaction prod-
ucts is also relevant at temperatures below 25°C.
Author Contributions
Conceptualization:GK.
Funding acquisition: JPA.
Investigation: GK.
Methodology:GK JPA.
Project administration: JPA.
Resources:GK RtH AB KW JPA.
Supervision:HWFGFAK JPA.
Validation: GK RtH AB KW.
Visualization:GK.
Writing – original draft:GK.
Writing – review& editing:GK RtH AB KWHWFGFAK JPA.
References
1. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of stable lyophilized
protein formulations: theory and practice. Pharmaceutical biotechnology. 2002; 13:109–33. doi: 10.
1007/978-1-4615-0557-0_5 PMID: 11987749.
Fig 4. A.T = 1 month (60˚C) TNF binding assay of reconstituted freeze-dried in vials Infliximab formulations
after storage for 1 month at 60˚C. Control: Infliximab (AIMM, stored at 4˚C), Freeze-dried (vials): sucrose-
based (F1), sucrose-inulin (F2) and sucrose-dextran (F3). B.T = 1 month (60˚C) TNF binding assay of
reconstituted freeze-dried Lyoguard trays Infliximab formulations after storage for1 month at 60˚C. Control:
Infliximab (AIMM, stored at 4˚C), Freeze-dried (Lyoguard trays): sucrose-inulin (L2) and sucrose-dextran
(L3). C. T = 1 month (60˚C) TNF binding assay of reconstituted spray-dried Infliximab formulations after
storage for1 month at 60˚C. Control: Infliximab (AIMM, stored at 4˚C), Spray–dried: sucrose-inulin (S1) and
sucrose-dextran (S2).
doi:10.1371/journal.pone.0163109.g004
Spray-Drying and Freeze-Drying of Infliximab
PLOS ONE | DOI:10.1371/journal.pone.0163109 October 5, 2016 12 / 14
2. Wang W. Lyophilization and development of solid protein pharmaceuticals. International journal of
pharmaceutics. 2000; 203(1–2):1–60. doi: 10.1016/s0378-5173(00)00423-3 PMID: 10967427.
3. Heljo VP, Harju H, Hatanpaa T, Yohannes G, Juppo AM. The effect of freeze-drying parameters and
formulation composition on IgG stability during drying. European journal of pharmaceutics and bio-
pharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV.
2013; 85(3 Pt A):752–5. doi: 10.1016/j.ejpb.2013.03.033 PMID: 23623795.
4. Patel SM, Pikal MJ. Emerging freeze-drying process development and scale-up issues. AAPS
PharmSciTech. 2011; 12(1):372–8. doi: 10.1208/s12249-011-9599-9 PMID: 21347620; PubMed Cen-
tral PMCID: PMC3066344.
5. Tsinontides SC, Rajniak P, Pham D, Hunke WA, Placek J, Reynolds SD. Freeze drying—principles
and practice for successful scale-up to manufacturing. International journal of pharmaceutics. 2004;
280(1–2):1–16. doi: 10.1016/j.ijpharm.2004.04.018 PMID: 15265542.
6. Pisano R, Fissore D, Barresi AA, Rastelli M. Quality by design: scale-up of freeze-drying cycles in
pharmaceutical industry. AAPS PharmSciTech. 2013; 14(3):1137–49. doi: 10.1208/s12249-013-0003-
9 PMID: 23884856; PubMed Central PMCID: PMC3755168.
7. Pisano R, Fissore D, Barresi AA, Brayard P, Chouvenc P, Woinet B. Quality by design: optimization of
a freeze-drying cycle via design space in case of heterogeneous drying behavior and influence of the
freezing protocol. Pharmaceutical development and technology. 2013; 18(1):280–95. doi: 10.3109/
10837450.2012.734512 PMID: 23078169.
8. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine
powder formulations: challenges and possibilities. Pharmaceutical research. 2008; 25(6):1256–73.
doi: 10.1007/s11095-008-9559-6 PMID: 18338241; PubMed Central PMCID: PMC2346510.
9. Etzl EE, Winter G, Engert J. Toward intradermal vaccination: preparation of powder formulations by
collapse freeze-drying. Pharmaceutical development and technology. 2014; 19(2):213–22. doi: 10.
3109/10837450.2013.769567 PMID: 23432539.
10. <Chapter_12_LyophilizationOfPharmaceuticalandBiologicalProducts_web.pdf>.
11. Draber P, Draberova E, Novakova M. Stability of monoclonal IgM antibodies freeze-dried in the pres-
ence of trehalose. Journal of immunological methods. 1995; 181(1):37–43. doi: 10.1016/0022-1759
(94)00326-r PMID: 7730665.
12. Gikanga B, Turok R, Hui A, Bowen M, Stauch OB, Maa YF. Manufacturing of High-Concentration
Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale. PDA J Pharm
Sci Technol. 2015; 69(1):59–73. doi: 10.5731/pdajpst.2015.01003 PMID: 25691715.
13. Maa YF, Bowen M, Turok R. Spray drying of monoclonal antibodies:Investigating powder-based bio-
logic drug substance bulk storage. Drying Technology. 2013; 31:1441–50. doi: 10.1080/07373937.
2013.796968
14. Gutka H, Prasad K. Current Trends and Advances in Bulk Crystallization and Freeze-Drying of Bio-
pharmaceuticals. In: Varshney D, Singh M, editors. Lyophilized Biologics and Vaccines: Springer
New York; 2015. p. 299–317.
15. Maa YF, Costantino HR, Nguyen PA, Hsu CC. The effect of operating and formulation variables on the
morphology of spray-dried protein particles. Pharmaceutical development and technology. 1997; 2
(3):213–23. doi: 10.3109/10837459709031441 PMID: 9552449.
16. Masters K. Spray drying handbook. 5th ed. Burnt Mill, Harlow, Essex, England New York: Longman
Scientific & Technical; Wiley; 1991. xiv, 725 p. p.
17. Vehring R. Pharmaceutical particle engineering via spray drying. Pharmaceutical research. 2008; 25
(5):999–1022. doi: 10.1007/s11095-007-9475-1 PMID: 18040761; PubMed Central PMCID:
PMC2292490.
18. Katja S. Spray drying of protein precipitates and evaluation of the nano spray dryer B-90. Dissertation,
LMU Munich. 2011.
19. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. Journal
of pharmaceutical sciences. 2007; 96(1):1–26. doi: 10.1002/jps.20727 PMID: 16998873.
20. Maa YF, Prestrelski SJ. Biopharmaceutical powders: particle formation and formulation consider-
ations. Current pharmaceutical biotechnology. 2000; 1(3):283–302. doi: 10.2174/1389201003378898
PMID: 11469385.
21. Duddu SP, Zhang G, Dal Monte PR. The relationship between protein aggregation and molecular
mobility below the glass transition temperature of lyophilized formulations containing a monoclonal
antibody. Pharmaceutical research. 1997; 14(5):596–600. PMID: 9165529.
22. Molina M, Armstrong TK, Zhang Y, Patel MM, Lentz YK, Anchordoquy TJ. The stability of lyophilized
lipid/DNA complexes during prolonged storage. Journal of pharmaceutical sciences. 2004; 93
(9):2259–73. doi: 10.1002/jps.20138 PMID: 15295787.
Spray-Drying and Freeze-Drying of Infliximab
PLOS ONE | DOI:10.1371/journal.pone.0163109 October 5, 2016 13 / 14
23. Carpenter JF, Crowe JH. An infrared spectroscopic study of the interactions of carbohydrates with
dried proteins. Biochemistry. 1989; 28(9):3916–22. doi: 10.1021/bi00435a044 PMID: 2526652.
24. Grasmeijer N, Stankovic M, de Waard H, Frijlink HW, Hinrichs WL. Unraveling protein stabilization
mechanisms: vitrification and water replacement in a glass transition temperature controlled system.
Biochimica et biophysica acta. 2013; 1834(4):763–9. doi: 10.1016/j.bbapap.2013.01.020 PMID:
23360765.
25. Hinrichs WL, Prinsen MG, Frijlink HW. Inulin glasses for the stabilization of therapeutic proteins. Inter-
national journal of pharmaceutics. 2001; 215(1–2):163–74. doi: 10.1016/s0378-5173(00)00677-3
PMID: 11250102.
26. Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab.
Clinical and experimental gastroenterology. 2014; 7:359–67. doi: 10.2147/CEG.S45297 PMID:
25258548; PubMed Central PMCID: PMC4171998.
27. Maurer JM, Hofman S, Schellekens RC, Tonnis WF, Dubois AO, Woerdenbag HJ, et al. Development
and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility
study. International journal of pharmaceutics. 2016; 505(1–2):175–86. doi: 10.1016/j.ijpharm.2016.03.
027 PMID: 26997425.
28. Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: Where we are after almost
100years of attempts. Adv Drug Deliv Rev. 2016; 101:108–21. doi: 10.1016/j.addr.2016.01.010 PMID:
26826437.
29. Hinz DC. Evaluation of methods for the determination of water in substances with unknown chemical
and thermal behaviour. Journal of pharmaceutical and biomedical analysis. 2007; 43(2):779–83. doi:
10.1016/j.jpba.2006.08.002 PMID: 16956740.
30. May JC, Wheeler RM, Etz N, Del Grosso A. Measurement of final container residual moisture in
freeze-dried biological products. Developments in biological standardization. 1992; 74:153–64. PMID:
1592165.
31. Schule S, Schulz-Fademrecht T, Garidel P, Bechtold-Peters K, Frieb W. Stabilization of IgG1 in spray-
dried powders for inhalation. European journal of pharmaceutics and biopharmaceutics: official journal
of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2008; 69(3):793–807. doi: 10.
1016/j.ejpb.2008.02.010 PMID: 18477504.
32. Mensink MA, Frijlink HW, van der Voort Maarschalk K, Hinrichs WL. Inulin, a flexible oligosaccharide I:
Review of its physicochemical characteristics. Carbohydrate polymers. 2015; 130:405–19. doi: 10.
1016/j.carbpol.2015.05.026 PMID: 26076642.
33. Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, Romeijn S, et al. Small amounts of sub-visible
aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharmaceutical
research. 2015; 32(4):1383–94. doi: 10.1007/s11095-014-1541-x PMID: 25319104.
34. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. The AAPS journal. 2006; 8
(3):E501–7. doi: 10.1208/aapsj080359 PMID: 17025268; PubMed Central PMCID: PMC2761057.
Spray-Drying and Freeze-Drying of Infliximab
PLOS ONE | DOI:10.1371/journal.pone.0163109 October 5, 2016 14 / 14
